A Placebo-Controlled Trial of Simvastatin Therapy in Smith-Lemli-Opitz Syndrome

BACKGROUND: Smith-Lemli-Opitz syndrome (SLOS) is a multiple malformation/cognitive impairment syndrome characterized by the accumulation of 7-dehydrocholesterol (7DHC), a precursor sterol of cholesterol. Simvastatin, an HMG-CoA reductase inhibitor that crosses the blood-brain-barrier, has been propo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wassif, Christopher A., Kratz, Lisa, Sparks, Susan E., Wheeler, Courtney, Bianconi, Simona, Gropman, Andrea, Calis, Karim A., Kelley, Richard I., Tierney, Elaine, Porter, Forbes D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303568/
https://www.ncbi.nlm.nih.gov/pubmed/27513191
http://dx.doi.org/10.1038/gim.2016.102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303568/
https://www.ncbi.nlm.nih.gov/pubmed/27513191
http://dx.doi.org/10.1038/gim.2016.102

Ejemplares similares